

Marianna Avitabile

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4958487/marianna-avitabile-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12
papers

154
citations

8
h-index

12
g-index

12
ext. papers

207
ext. citations

5.5
avg, IF

2.24
L-index

#	Paper	IF	Citations
12	FGFR1 is a potential therapeutic target in neuroblastoma.. <i>Cancer Cell International</i> , 2022 , 22, 174	6.4	1
11	Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma. <i>Journal of Cancer</i> , 2020 , 11, 1495-1504	4.5	7
10	Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4072-4081	5.6	8
9	Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma. <i>Cancer Research</i> , 2020 , 80, 382-393	10.1	7
8	Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. <i>Genes</i> , 2019 , 10,	4.2	8
7	HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. <i>BMC Medical Genetics</i> , 2019 , 20, 37	2.1	20
6	A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1405-1415	6.1	18
5	Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. <i>International Journal of Cancer</i> , 2018 , 143, 2828-2837	7.5	34
4	Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. <i>Carcinogenesis</i> , 2017 , 38, 1011-1020	4.6	13
3	CD55 is a HIF-2 α marker with anti-adhesive and pro-invading properties in neuroblastoma. <i>Oncogenesis</i> , 2016 , 5, e212	6.6	6
2	Proteomic Alterations in Response to Hypoxia Inducible Factor 2 α in Normoxic Neuroblastoma Cells. <i>Journal of Proteome Research</i> , 2016 , 15, 3643-3655	5.6	8
1	Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. <i>Scientific Reports</i> , 2015 , 5, 11158	4.9	24